Sökning: id:"swepub:oai:DiVA.org:uu-317715" >
Degarelix monothera...
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer : an analysis of two randomized controlled trials
-
- Iversen, Peter (författare)
- Univ Copenhagen, Rigshosp, Copenhagen Prostate Canc Ctr, Copenhagen, Denmark.
-
- Damber, Jan-Erik, 1949 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology
-
- Malmberg, Anders (författare)
- Ferring Pharmaceut, Copenhagen, Denmark.
-
visa fler...
-
- Persson, Bo-Eric (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Lakarhuset & Uppsala Univ, Lakarhuset Urol, St Persgatan 17,5, SE-75320 Uppsala, Sweden.
-
- Klotz, Laurence (författare)
- Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON, Canada.
-
visa färre...
-
Univ Copenhagen, Rigshosp, Copenhagen Prostate Canc Ctr, Copenhagen, Denmark Institutionen för kliniska vetenskaper, Avdelningen för urologi (creator_code:org_t)
- 2015-12-16
- 2016
- Engelska.
-
Ingår i: THERAPEUTIC ADVANCES IN UROLOGY. - : SAGE Publications. - 1756-2872 .- 1756-2880. ; 8:2, s. 75-82
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://journals.sag...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://gup.ub.gu.se...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: The objective of this study was to assess differences in efficacy outcomes between luteinizing hormone-releasing hormone (LHRH) agonist plus antiandrogen (AA) flare protection and monotherapy with the gonadotrophin-releasing hormone antagonist degarelix in patients with prostate cancer. Methods: Data from 1455 patients were pooled from two prospective, phase III randomized 1-year clinical trials of degarelix versus LHRH agonist with or without AA. The AA bicalutamide was administered at the investigator's discretion. Adjusted hazard ratios (HRs) were calculated using a Cox proportional hazards regression model and a conditional logistic regression model was used for a case-control analysis of odds ratios (ORs). Results: Patients received degarelix monotherapy (n = 972) or LHRH agonist (n = 483) of whom 57 also received AA. Overall, prostate-specific antigen progression-free survival (PSA PFS) was improved with degarelix versus LHRH agonist + AA (Cox proportional hazards regression model-adjusted HR for PSA PFS failure was 0.56 [95% confidence interval (CI) 0.33-0.97, p = 0.038]). To compensate for a higher proportion of patients with metastases, Gleason score 7-10, and PSA >20 ng/ml in the LHRH agonist + AA group, a case-control analysis using a conditional logistic regression model was utilized. This resulted in an OR for PSA PFS of 0.42 (95% CI 0.20-0.89; p = 0.023) in the overall population, and 0.35 (95% CI 0.13-0.96; p = 0.042) in patients with PSA >50 ng/ml at baseline, when treated with degarelix versus LHRH agonists + AA. There were a small number of deaths, 1.9% with degarelix and 7% with LHRH agonists + AA (case-control analysis OR = 0.37; p = 0.085). Conclusions: Degarelix monotherapy produced a more favorable effect on PSA PFS outcomes than a LHRH agonist + AA flare protection therapy in patients with prostate cancer when a case-control analysis was used to compensate for differences between treatment groups.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- anti-androgen
- degarelix
- luteinizing hormone-releasing hormone agonist
- prostate cancer
- testosterone flare
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas